Trial Profile
A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2022
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 26 Aug 2022 According to ClinicalTrials.gov, protocol has been amended as addition in primary end points as Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Emergent Treatment Related AEs and Treatment Emergent Treatment Related SAEs, Grade 3 or 4 TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4, TEAEs Leading to Dose Reduction, LFT etc.
- 28 Jul 2021 Status changed from recruiting to completed.
- 21 Jun 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.